STORM Therapeutics selects first-in-class clinical candidate targeting METTL3
Cambridge, UK. 22 October 2020. Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced that STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies. The Company intends to submit an IND […]
STORM Therapeutics selects first-in-class clinical candidate targeting METTL3 Read More »